![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Warns Stemell for Unapproved Stem Cell Products
FDA Warns Stemell for Unapproved Stem Cell Products
September 9, 2019
The FDA hit California-based stem cell company Stemell with a warning letter for deviations from current good tissue practices and current good manufacturing practices.
The agency found the company’s StemL UCB-Plus and StemL UCT-Plus to be unapproved drugs derived from umbilical-cord blood and umbilical-cord.
The FDA inspected the San Juan Capistrano facility in March and found deficient donor eligibility practices, unvalidated manufacturing processes, deficient environmental monitoring and inadequate aseptic processes.
Upcoming Events
-
21Oct